INDICATIONS: Spectral F7 is indicated to maximize benefits for people already using a primary hair-follicle therapy such as Spectral DNC, and it can serve as an effective stand-alone treatment in the early stages of thinning.
ACTIVITIES: Men and women concerned about hair shedding and follicle health add Spectral F7 to their treatments because it is the first topical solution for human use to incorporate astressin-B. The complex peptide (protein fragment) has shown in trials that it blocks receptors for corticotropin-releasing factor (CRF), involved in the stress response. A newly published clinical study investigated whether CRF blockade might influence hair growth when stress hormones in laboratory animals are over-expressed. Results of the investigation, conducted in vivo, show that astressin-B does offer a promising new mechanism of action to treat atrophic hair follicles. The release of Spectral.F7 means that customers of DS Laboratories are the first to benefit from this major new advance in the art and science of hair growth.